Oxygen-ozone autohaemotherapy in fibromyalgia: safety profile and adverse events. A scoping review | Canada Hyperbarics Skip to main content
Review Clin Exp Rheumatol 2026

Oxygen-ozone autohaemotherapy in fibromyalgia: safety profile and adverse events. A scoping review

Casale R, Petrikonis K, Ahmadian A, Bazzichi L, Sarzi-Puttini P — Clin Exp Rheumatol, 2026

Tier 2, Indexed

Automatically imported from PubMed based on relevance criteria.

Summary

What Researchers Did

Researchers conducted a scoping review to systematically evaluate the documented adverse events and assess the risks associated with oxygen-ozone autohaemotherapy (O2-O3-AHT) for fibromyalgia.

What They Found

The review identified predominantly case reports detailing rare but potentially serious adverse events linked to O2-O3-AHT. These included haemolysis and renal failure (often with ozone concentrations over 60 μg/mL), hyperkalaemia in patients with existing health conditions, myocardial infarction, cerebral gas embolism, autonomic reactions, anaphylactic reactions, and infectious complications due to protocol breaches. The overall incidence of serious adverse events could not be reliably quantified due to a lack of prospective registries and reliable data.

Canadian Relevance

No direct Canadian connection identified.

Study Limitations

The overall incidence of serious adverse events cannot be reliably quantified given the absence of prospective registries and reliable denominator data.

This plain-language summary is generated with AI assistance and checked against the source abstract before publication. See our editorial policy.

Was this summary helpful?

Study Details

Study Type Review
Category Neurological
Source Pubmed
PubMed ID 42328943
Year Published 2026
Journal Clin Exp Rheumatol
MeSH Terms Humans; Fibromyalgia; Ozone; Treatment Outcome; Oxygen; Blood Transfusion, Autologous; Risk Factors; Risk Assessment

Cite This Study

Share
Discuss with a qualified healthcare professional. Then: Review Coverage Guide View Recognised Conditions

Disclaimer: This study summary is provided for informational and educational purposes only. It does not constitute medical advice. The information presented reflects the findings of the original research authors and may not represent the views of Canada Hyperbarics. Always consult a qualified healthcare professional before making treatment decisions.

Last reviewed: June 26, 2026 | Reviewed by: Canada Hyperbarics Editorial Team | Editorial process | Research sources | Counts & methodology